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Corticospinal motor neurons (CSMN) have a unique ability to receive, integrate, translate,
and transmit the cerebral cortex’s input toward spinal cord targets and therefore act as
a “spokesperson” for the initiation and modulation of voluntary movements that require
cortical input. CSMN degeneration has an immense impact on motor neuron circuitry
and is one of the underlying causes of numerous neurodegenerative diseases, such
as primary lateral sclerosis (PLS), hereditary spastic paraplegia (HSP), and amyotrophic
lateral sclerosis (ALS). In addition, CSMN death results in long-term paralysis in spinal
cord injury patients. Detailed cellular analyses are crucial to gain a better understanding
of the pathologies underlying CSMN degeneration. However, visualizing and identifying
these vulnerable neuron populations in the complex and heterogeneous environment of
the cerebral cortex have proved challenging. Here, we will review recent developments
and current applications of novel strategies that reveal the cellular and molecular basis of
CSMN health and vulnerability. Such studies hold promise for building long-term effective
treatment solutions in the near future.
Keywords: corticospinal motor neuron, genetic labeling, retrograde labeling, motor neuron disease, upper motor
neurons
INTRODUCTION
Our expertise in the precise control of finemovement sets us apart
from other mammals. Voluntary movement is initiated, mod-
ulated, and controlled via a very complicated neural network,
called the motor neuron circuitry, which includes neurons and
cells that are located both in the cerebral cortex and the spinal
cord. The output of neuron function is manifested bymuscle con-
traction leading to precise movement of the legs, arms, and hands.
It is this circuitry that helps define us as human beings by giving
us a unique advantage to build and create tools and to express
ourselves.
Since cognitive abilities are reflected in our actions, it is unrea-
sonable to think that only one neuron type in the brain would be
responsible for movement. Among all other neuron types in the
cerebral motor cortex, however, one neuron population stands
out with its unique abilities and function. These neurons are char-
acterized by: (1) a large pyramidal cell body, (2) a single apical
dendrite that extends toward layer I displaying major branch-
ing and arborization, especially within layer II/III, (3) numerous
basal dendrites arising from the basolateral surface, and most
impressively (4) a very long axon that projects toward spinal cord
targets (Molnar and Cheung, 2006; Ozdinler and Macklis, 2006;
Molyneaux et al., 2007). These neurons, known as Betz cells in
humans, are located in layer V of the motor cortex. They are also
referred to as the upper motor neurons, corticospinal neurons,
and corticospinal projection neurons. We prefer using the name
corticospinal motor neurons (CSMN) due to their unique ability
and function and to emphasize their role within themotor neuron
circuitry.
CSMN are special neuron populations in our cerebral cortex
that can collect, integrate, translate, and transmit both the exci-
tatory and the inhibitory cortical inputs as one single message
to long distance spinal cord targets. This distinct ability allows
them to act as the “spokesperson” of the cerebral cortex for the
motor function. Without CSMN, especially in humans, the con-
nection between the cerebral cortex and the spinal cord would
be greatly impaired. Therefore, to emphasize the importance of
cortical input to the motor neuron circuitry, we think the word
“motor” is necessary when naming these long distance projection
neurons of the cerebral cortex.
CSMN are heavily modulated by local neuron circuitry and
long distance projection neurons, including, but not restricted to,
thalamocortical neurons and callosal projection neurons (CPN)
(Figure 1A). While details are still emerging about the tim-
ing and extent of CSMN regulation, anatomical studies suggest
that the major excitatory input to CSMN is mediated by neu-
rons located in layer II/III and layer V of the motor cortex
(Thomson and Lamy, 2007; Shepherd, 2011). Thalamacortical
neurons are important in carrying cognitive and sensory infor-
mation to CSMN via neuronal networks that include cerebellum
and basal ganglia (Clasca et al., 2012). The heterogeneity of
these neurons in terms of somatodendritic morphology, axonal
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FIGURE 1 | Schematic and simplified representation of CSMN
modulation by local neuronal circuitries and long-range projection
neurons in normal physiological conditions and in disease. (A)
Thalamocortical projections provide excitatory input to CSMN. The site of
neuronal modulation is suggested to be mainly within layer II/III and layer V.
CSMN are also heavily modulated by both ipsi and contralateral callosal
projection neurons that are mainly located within layer II/III and layer V of the
cerebral cortex. Local circuitry neurons also modulate CSMN activity either
directly or via an interneuron. In particular, LTS (low-threshold-spiking) and FS
(fast-spiking) interneurons are differentially involved in the inhibitory
microcircuit. While LTS interneurons receive interlaminar input from layer II/III
projection neurons, FS receive intralaminar input from CSMN illustrating a
possible distinct mechanism for disynaptic CSMN inhibition. Excitatory inputs
impinge mainly upon the spines that are located on the dendrites located in
layer II/III and layer V, and inhibitory input is conveyed mainly on the spines
that are directly located on the apical dendrite and on a subset of spines that
are present on basal dendrites. (B) In ALS, CSMN show vulnerability and
undergo progressive degeneration. At pre-symptomatic stage (i.e., P60)
CSMN display major spine loss within apical, but not basal, dendrites and
apical dendrites undergo massive vacuolation and lose cytoarchitectural
integrity. Such cellular defects would have profound impact on CSMN
modulation. How circuitries are affected in disease require further
investigation. Excitatory and inhibitory input is denoted by lines and dashed
lines, respectively.
branching, and laminar specificity is of great importance. Subtle
differences within the same neuron population could account for
the variations of thalamacortical input to CSMN.
Another excitatory input is provided by CPN, which include
ipsi- and contralateral projections (Anderson et al., 2010). CPN
are highly heterogeneous, ranging from small to medium size,
and are primarily located in all layers of the cortex, but most
prominently in layer V and II/III. They carry integrative circuitry
information (Arlotta et al., 2005; Molyneaux et al., 2007). This
neuron population is closely related to CSMN; CPN are born
from the same progenitor pool, migrate together in the devel-
oping cerebral cortex, and a subset of CPN reside together with
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CSMN in layer V. However, CPN project to the contralateral side
of the cerebral hemisphere and display a different function in
cognition, perception, and higher-order thinking.
In addition to long distance projection neurons, local cir-
cuitry neurons also have direct input to CSMN. Such neuronal
interactions are rather interesting, as they can be mediated both
directly and through a secondary neuron population. There is
also CSMN-CSMN interaction, as nearby CSMN communicate
with each other (Kiritani et al., 2012). Such interactions, which
mostly occur within layer V of the motor cortex, could serve both
as feedback and feed forward loops (Figure 1A).
Modulation of CSMN function involves a delicate and
continuous balance between excitatory and inhibitory inputs.
Interneurons account for about 20% of the cortical neuron pop-
ulation (Ikrar et al., 2011), and they are subdivided according
to their anatomical location, cell morphology, specific-marker
expression, dendritic arborization, and targeting of different sites
and compartments of the cortical neurons including CSMN
(Markram et al., 2004). Fast-spiking (FS) and low-threshold-
spiking (LTS) are two types of interneurons that are implicated in
CSMN inhibitory pathways (Tanaka et al., 2011). FS neurons have
a high number of local connections to CSMN when compared to
LTS. Recent studies designed to dissect out inhibitory inputs con-
verging to CSMN have shown that these FS and LTS differentially
inhibit CSMN (Apicella et al., 2012). While interlaminar input
of pyramidal neurons in the layer II/III via LTS neurons provides
disynaptic inhibition to CSMN (layer II/III→layer V), intralami-
nar input to FS fromCSMN (layer V→layer V) delivers inhibition
to CSMN in a feed forward manner (Figure 1A).
The progressive degeneration of CSMN is accepted as one of
the major characteristics of neurodegenerative diseases affecting
voluntary movement that require CSMN input to the motor neu-
ron circuitry. For example, hereditary spastic paraplegia (HSP)
is best characterized by the progressive degeneration of CSMN
(Fink, 2001). The disease manifests itself with stiffness in the
legs, paralysis and motor function defects. Primary lateral sclero-
sis (PLS) is also characterized by CSMN death and corticospinal
tract (CST) degeneration. However, in amyotrophic lateral sclero-
sis (ALS) both the spinal and cortical motor neurons progressively
degenerate (Udaka et al., 1986; Brown and Robberecht, 2001),
adding complexity to the disease (Eisen and Weber, 2001; Ravits
et al., 2007). Although spinal muscular atrophy (SMA) has been
characterized by prominent spinal motor neurons (SMN) degen-
eration, recent evidence also suggests the involvement of CSMN
(D’Errico et al., 2013). Lastly, exome sequencing analysis of
patients with HSP revealed numerous shared common pathways
and molecular networks that are also involved in ALS as well
as Alzheimer’s disease and Parkinson’s disease (Novarino et al.,
2014). This is a remarkable finding as it links numerous disorders
at a molecular level. CSMN are clinically important and relevant
neuron population that deserve immediate attention to improve
future therapeutic applications both in injury and disease. If we
can understand the molecular mechanisms responsible for their
cellular vulnerability and degeneration, then we may begin to
unravel the basis of numerous disease pathologies.
Even though mechanisms of CSMN modulation by cortical
neurons is beginning to emerge, it is still not clear how that
cortical connectivity and communication is hampered during dis-
ease. Since CSMN receive most of their input from the apical
dendrite, cellular degeneration, disintegration of apical dendrite
and spine loss would have significant consequences on the trans-
fer of cortical signals to the spinal cord targets (Figure 1B). This
indeed could be one of the reasons for a dysfunctional motor
neuron circuitry and voluntary movement defects.
While CSMN are a crucial component of the motor neu-
ron circuitry, they are not equally central in all species (Lemon,
2008). In rodents, the CST projects through the striatum, inter-
nal capsule, pons and pyramidal decussation, and subsequently
descends in the ventral part of the dorsal column (Jones et al.,
1982; Stanfield, 1992; Terashima, 1995). In humans, these projec-
tions descend laterally, and more than 80% of the axon fibers that
originate from the CSMN in the motor cortex connect directly
with SMN in the spinal cord (Lemon, 2008). This difference in
projection paths affects neuronal circuits and connections defin-
ing the speed, specificity, and mode of action. Humans are very
dexterous with their hands, but are mostly vulnerable to any
injury that damages the CST. CSMN numbers are very lim-
ited in the cerebral cortex and their cellular degeneration results
in severe consequences and is central to numerous neurode-
generative diseases and injury. For example, CSMN health and
connectivity are hampered during spinal cord injury. Lesions of
the CST result in deterioration in speed, force, and movement
coordination (Lemon, 2008). One of the reasons for long-term
paralysis in patients is the cellular degeneration of CSMN and
the impaired connection between the cerebral cortex and the
spinal cord.
We enter a new era of very exciting times in CSMN biol-
ogy. Historically, there were serious limitations that hindered
detailed studies of CSMN. Their importance as a neuron popula-
tion was not well appreciated, and applications that allowed their
cellular analysis were not available. Recently, numerous novel
techniques and approaches to help identify and visualize CSMN
within the complex structure of the cerebral cortex have been
developed. AAV-mediated gene delivery and novel reporter lines
now have the potential to change the future of CSMN inves-
tigations. In this review, we will introduce and describe these
innovative approaches and comparatively discuss their limita-
tions and advantages for future cellular analysis and therapeutic
applications.
RETROGRADE LABELING APPROACHES
With their axons projecting to distant targets, projection neu-
rons are one of the most polarized cells in the body and highly
depend on axonal transport to maintain cellular homeostasis.
Retrograde transport depends on neurons’ ability to carry pro-
teins and molecules from the tip of the axon all the way back to
the soma. Early studies revealed the basics of this cellular process
in the central nervous system (Lavail and Lavail, 1972). Soon after,
the ability of axons to uptake and retrogradely transport tracers
and molecular dyes was uncovered making it possible to label,
identify, and visualize neurons of interest based on their projec-
tion path and the pattern of their target innervation (Lavail et al.,
1973). Retrograde transport studies demonstrated the impor-
tance of growth factors for the development and maturation of
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neurons. For example, when retrograde transport of nerve growth
factor (NGF) to the cell body was revealed, the field opened up to
a new idea that this phenomenon was actually critically important
for the maintenance of neuronal health and function (Paravicini
et al., 1975; Stoeckel and Thoenen, 1975), and it was possi-
ble for the axon to retrogradely transport large target-derived
macromolecules important for their survival and differentiation
(Hendry and Hill, 1980). The potential consequence of axonal
transport defects became an area of interest (McLeod, 1975) and
continues to be so with the identification of its association with a
vast majority of neurodegenerative diseases (Morfini et al., 2009).
In addition, identification of intrinsic differences between axonal
transport of proteins in sensory and motor axons was remarkable
as it pointed out the specificities of this phenomenon in different
neuron populations (Bisby, 1977).
The anatomical knowledge of the timing and extent of axonal
elongation, as well as the neuron’s ability to perform retrograde
transport, formed the basis of the initial studies that discern
a distinct neuron population among many other neuron types.
Horseradish peroxidase (HSP) was one of the first reagents used
to study retrograde axonal transport and to visualize the cell
bodies of projection neurons (Bunt et al., 1974; Kristensson
and Olsson, 1974; Lavail and Lavail, 1974). Tetanus toxin and
3H-proline were introduced as agents that can be retrogradely
transported in the axon (Kunzle, 1977; Price and Griffin, 1977)
and were widely used in retrograde labeling studies, especially
those showing transsynaptic transfer of tetanus toxin. These stud-
ies generated interest in its use to determine neuronal connections
(Schwab et al., 1979).
The first fluorescent retrograde labeling was performed using
red fluorescent Evans blue and blue fluorescent DAPI-primuline
injections dramatically improving visualization of cells and the
extent of their branching (van der Kooy and Kuypers, 1979). Since
then, numerous reagents with different fluorescent properties
have been used to retrogradely label neurons. For example, the
Bisbenzimide and “nuclear yellow” produced green and golden-
yellow labeling, respectively. True Blue, Fast Blue, and Fluoro-
Gold (FG) produced blue retrograde labeling (Kuypers et al.,
1980). Availability of different dyes with different colors allowed
double and triple labeling experiments to study the details of
axonal projection paths and to reveal the identity of neurons (De
Olmos and Heimer, 1980). The disadvantages of these early dyes
were their diffusion and lack of sustained stability within the cell,
which limited their use in connectivity mapping studies.
The use of modern fluorescent tracers, such as latex-
based microspheres (Lanciego and Wouterlood, 2011) and FG
(Catapano et al., 2002), have been themost common approach for
projection neuron labeling. FG and microspheres are taken up by
axons and retrogradely transported to the cell body by fast axonal
transport. These dyes aremostly engulfed in lysosomes that fill the
somata with stable fluorescence. For example, injection of fluores-
cent microspheres into the contralateral hemisphere of the motor
cortex or spinal cord provided labeling of two distinct project-
ing neuron populations: CPN and CSMN, respectively (Catapano
et al., 2001; Arlotta et al., 2005; Ozdinler andMacklis, 2006).More
recently, a novel immunopanningmethod to culture CSMN com-
bined injection of cholera toxin β (CTB) conjugated to fluorescent
microspheres to target the axonal tract of CSMN (Dugas et al.,
2008), and CSMN containing CTB were then immunopanned
with anti-CTB antibody to yield pure populations of CSMN.
A new era of systems biology began to emerge in the 1970s
as the connections among neurons that are located far apart
were illuminated. Retrograde labeling and tracing studies began
to reveal the unaccounted extent of connectivity in the central
nervous system (Cull, 1975; Yorke and Caviness, 1975; Somogyi
et al., 1979). Very systematic and well-defined investigations ini-
tiated the early stages of cortical connection mapping studies
(Broadwell, 1975; Bunt et al., 1975; Liedgren et al., 1976; Walberg
et al., 1976; Wise and Jones, 1976), laying the foundation for
our current understanding and also identifying defects that occur
in the presence of mutations in key genes (Caviness and Yorke,
1976). In addition, dual labeling approaches began to demon-
strate the relationship between two different neuron populations
located in the same nucleus suggesting that they can have differ-
ent functions and mode of actions (Steiger and Buttner-Ennever,
1978).
Retrograde labeling approaches also helped investigations of
different neuron populations that are located in various regions
of the nervous system and project to different targets, includ-
ing the muscle. Injection of HSP into the developing limb of
the chick embryo enabled the first cellular labeling of develop-
ing spinal motor neurons (Oppenheim and Heaton, 1975) and
the detailed analysis showed the timing and extent of their devel-
opment and projection (Landmesser, 1978). Similarly, trochlear
motor neurons were first visualized by retrograde labeling using
HSP (Sohal and Holt, 1978). The early postnatal development of
motor neurons located in the facial nucleus of the brainstem were
also studied with similar retrograde labeling approaches (Olsson
and Kristensson, 1979).
Most relevant to this review, the origins of the pyramidal tract
were first determined by HRP retrograde labeling (Biedenbach
and Devito, 1980), and early studies employing double labeling
approaches demonstrated that in the cat, corticospinal neurons
were also present in the sensorimotor cortex, especially in area 3a
(Rustioni and Hayes, 1981). Similar experiments in rat demon-
strated the somatotopy of corticospinal projection neurons and
revealed that CSMN were located in layer Vb of the motor cortex
extending within the somatosensory cortex. Most impressively,
the neurons projecting to the cervical levels of the spinal cord
were located further away from the midline whereas the neu-
rons that projected to distal parts of the spinal cord were found
closer to the midline (Ullan and Artieda, 1981). Projection pat-
terns of neuron populations located in different areas of the brain,
such as the red nucleus, were also studied using double label-
ing. These approaches revealed the complexity of the descending
spinal pathways (Huisman et al., 1981) and originatedmany other
studies to understand the development and establishment of con-
nections in the motor neuron circuitry that control voluntary
movement.
Early and seminal studies, in which the CSMN of the monkey
were intracellularly filled with HRP and their anterograde axonal
projections were studied in the spinal cord, showed very clearly
that CSMN axons mainly terminate in lamina IX and make direct
contacts with spinal motor neurons in the spinal cord (Shinoda
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et al., 1981). Species-specific differences in axonal path forma-
tions, target innervations, and circuitry building also began to
emerge with the help of this approach (Jones and Leavitt, 1974).
The development of the pyramidal tract and neuronal connectiv-
ity was studied in many different species, including the hamster,
which can regenerate its pyramidal tract axons upon injury if it
occurs early in development (Reh and Kalil, 1981). Retrograde
labeling studies also enabled the comparative analysis of species
differences. Numerous studies using cats, mice, monkeys, and
hamsters demonstrated how these species-specific differences
affect neural connections and overall networks (Tolbert et al.,
1978; Beckstead et al., 1981).
The CST arises from CSMN located in layer V of the motor
cortex. CSMN are born at embryonic day (E) 13.5 in the mouse
and start migrating toward layer V of the motor cortex without
a major axonal projection (O’Leary and Koester, 1993). By E17,
CSMN axons reach the pons and CST axons enter the spinal cord
by postnatal day P0 and continue to elongate until P14. By P14,
even the most caudal targets in the spinal cord are innervated.
This information proves to be very useful when labeling CSMN at
different stages of their development. The other important infor-
mation is related to cellular identity. Even though CSMN can be
considered a “pure” neuron population, they are divided into sub-
groups that innervate different targets within the spinal cord: the
cervical, lumbar, and thoracic regions. There are several differ-
ences in the CST among species; the anatomical location of CST
fibers is in the dorsal columns of the spinal cord in mice, whereas
in primates and humans CST fibers are mostly located in the
lateral columns and about 10% descends ipsilaterally (Courtine
et al., 2007). The CSMN projection field has been extensively
studied in rodents. For instance, anterograde studies utilizing
HRP have demonstrated the projection field of CSMN in the
dorsal funiculus of the spinal cord in rats (Casale et al., 1988),
These studies were further confirmed using biotin dextran-amine.
CST fibers were found in on all levels of the spinal cord in rats
(Brosamle and Schwab, 1997) and mice (Liang et al., 2011). The
timing of CSMN axonal growth through the brain to the spinal
cord has also been demonstrated with anterograde techniques
(Canty and Murphy, 2008). Hence, the anatomical knowledge
of axonal projections and their timing is valuable for labeling
distinct projection neuron populations and for distinguishing dif-
ferent types of neurons that reside together in the cerebral cortex
but project to different areas in the central nervous system.
Understanding the details of CSMN connectivity also depends
on retrograde labeling approaches to reveal the location of
CSMN within the complex structure of the motor cortex.
Retrograde labeling of CSMN in adult mice also facilitated stud-
ies during adulthood and when CSMN are affected in disease
(Figures 2C–E). Studies using FG retrograde labeling demon-
strated the presence of CSMN in layer V of the motor cortex
under UV light (Figures 2F,G). In addition, FG visualization was
enhanced by immunocytochemistry with DAB (Figure 2H). This
allowed for visualization of CSMN somata and a portion of the
proximal apical dendrite, depending on the concentration and
elapsed time following FG injection. Using this approach, anal-
ysis of the hSOD1G93A ALS mouse model has demonstrated that
CSMN degeneration is pre-symtomatic and related to apoptotic
mechanisms (Ozdinler et al., 2011). During ALS pathology,
CSMN degenerate and there are patterns of cortical hyperex-
citability that suggest dysfunction of CSMN in the cerebral cortex
(Shepherd, 2013).
A wealth of information on CSMN biology has been generated
using retrograde labeling approaches coupled with numerous
applications. Since microspheres and FG fluorescently label cells,
projection neurons can be purified using fluorescent activated
cell sorting (FACS). In the case of CTB labeling, immunopan-
ning is used providing a higher yield than FACS. Tissue
culture approaches with CSMN purified using immunopan-
ning approach revealed details of their survival requirements
(Figures 2A,B) (Dugas et al., 2008), and FACS-purified CSMN
displayed axon elongation in the presence of insulin-like growth
factor 1 (IGF-1) and branching and arborization in the pres-
ence of brain-derived neurotrophic factor (BDNF) (Ozdinler and
Macklis, 2006). Lastly, microarray analysis coupled with FACS-
mediated purification of CSMN and CPN revealed the molecular
signatures of CSMN and the genes that are important for their
identification and early maturation (Arlotta et al., 2005).
Retrograde labeling coupled with electrophysiology are begin-
ning to elucidate details of CSMN biology. For example, laser-
scanning photostimulation in CSMN retrogradely labeled with
fluorescent microspheres revealed unique intrinsic properties of
CSMN when compared to CPN, such as differences in fast action
potentials, firing rates, and hyperpolarization activated current
modulation (Sheets et al., 2011; Suter et al., 2012).
Retrograde labeling techniques offer great advantages to study
CSMN both in vivo and in vitro, but it falls short on providing
the essential resolution to investigate the details of their cytoar-
chitecture. While the location of the cell body can be identified
by the presence of fluorescent microspheres and the apex of the
proximal apical dendrite can be visualized with FG labeling, they
do not reveal cellular details. Virus-mediated gene delivery is one
potential solution to this limitation.
AAV-MEDIATED RETROGRADE TRANSDUCTION
Adeno-associated viruses (AAV) have been considered for their
potential use in future therapeutic applications due to their
low toxicity and ability to transduce a wide variety of cells
(During and Leone, 1995; McCown, 2005; Han et al., 2010).
They have been widely used to deliver genes of interest into
the cerebral cortex of mice and rats for a variety of neu-
rodegenerative diseases, such as Parkinson’s disease (Mandel
et al., 1997; Wang et al., 2002a) and ALS (Wang et al., 2002b;
Boillee and Cleveland, 2004; Yamashita et al., 2013; Keifer et al.,
2014). Because of their application, mechanistic insights into the
pathologies that cause these diseases have been uncovered (Tatom
et al., 2009; Langou et al., 2010; Decressac et al., 2012; Davies et al.,
2013).
AAV have the potential to transduce a wide variety of cells
and neurons. One way to achieve specificity is by retrograde
transduction via injection into an axon tract selectively target-
ing only the cell bodies of neurons projecting through that tract.
AAV-mediated retrograde transduction requires binding of the
AAV to specific receptors on the axon surface and internaliza-
tion through a receptor-mediated mechanism. Another way to
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FIGURE 2 | CSMN retrograde labeling and transduction approaches.
(A) Schematic drawing of CTB injection conjugated to green fluorescent
microspheres into the pyramidal decussation of the spinal cord.
Retrograde labeled CSMN containing CTB on their surface can be
isolated by immunopanning. (B) Enlarge inset of the motor cortex
enlarged to the right. Modified from Dugas et al. (2008). (C) Schematic
drawing of retrograde labeling of CSMN by injection into the CST of the
cervical spinal cord (C2). (D) Injection is restricted to the CST that lies
within the dorsal funiculus (df). (E) Enlarged inset of the motor cortex
showing CSMN retrogadely labeled with red fluorescent microspheres.
(F) FG retrograde labeling. CSMN are visualized throughout the motor
cortex by direct analysis on fluorescent microscope. (G) Enlarged inset
of CSMN in the motor cortex. (H) CSMN cell body and proximal apical
dendrite structures are enhanced by FG immunocytochemistry using
DAB. (I) AAV-mediated retrograde transduction. CSMN are visualized
throughout the motor cortex by eGFP immunocytochemistry using
fluorescence microscopy. Large inset of a representative CSMN in the
right corner. (J) CSMN cytoarchitectural structure is enhanced by eGFP
immunocytochemistry using DAB. (K) large inset of a CSMN shows
details of CSMN cell body, basal dendrites, apical dendrite and spines.
Scale bars: (B) = 100μm, (E) = 50μm, (F) = 500μm, (G,H) = 50μm,
(I) = 100μm (inset = 20μm), (J) = 100μm, (K) = 20μm.
achieve specificity is by viral vector capsid engineering. Recent
advancements involving the discovery and generation of new AAV
serotypes offer potential applications for gene delivery in distinct
neuron populations (Weinberg et al., 2013). This is especially
important considering that in neurodegenerative diseases distinct
neuron populations show primary vulnerability and undergoes
neurodegeneration. The ability to target the neurons that are
vulnerable, without affecting other neurons, cells, and differ-
ent circuitries, would be critically important for building long-
term and effective therapeutic approaches. Here we will focus
on the use and application of AAV on the genetic modulation
of motor neurons and the components of the motor neuron
circuitry.
One of the pioneering works came from studies demonstrating
the ability to genetically label a distinct set of SMN by introducing
AAV into the muscle fibers they innervate (Martinov et al., 2002).
These studies were important as they show that AAV injected to
the muscle can retrogradely transduce SMN, and most impor-
tantly distinct set of motor neurons are transduced based on their
projection field. AAV that encode a gene of interest, such as glial-
derived neurotrophic factor (GDNF), were then delivered to the
muscle fibers to enhance growth factor expression in a distinct
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set of SMN (Lu et al., 2003), showing that it is indeed possible to
use AAV to retrogradely transduce SMN and induce selective gene
expression.
Neurotrophic growth factors that play key roles in the sur-
vival of motor neurons, including IGF-1, vascular endothelial
growth factor (VEGF), GDNF, and granulocyte-colony stimu-
lating factor (G-CSF), have been considered for ALS therapies
(Hester et al., 2009). AAV2-IGF-1 injected into the muscle of the
hSOD1G93A mouse retrogradely transduced SMN, increased life
span, and decreased disease progression were very encouraging
(Kaspar et al., 2003). Introduction of IGF-1 into the deep cere-
bellar nuclei, a region of the cerebellum with extensive brainstem
and spinal cord connection, via AAV suggested that the reduction
of ALS pathology was due in part to its activity on non-neuronal
cells in the CNS (Dodge et al., 2008) as it attenuated the release of
tumor necrosis factor-alpha (TNF-α) and nitric oxide.
AAV-mediated gene delivery approaches have been increas-
ingly used to modulate gene expression in SMN of ALS mouse
models. Most recently, intramuscular delivery of the AAV6 encod-
ing silencer shSOD1 RNA transduced SMN but failed to alter dis-
ease course in the hSOD1G93A mice (Towne et al., 2011). However,
these approaches have significant limitations as they only target
the SMN that innervate specific muscle groups. Intrathecal injec-
tions releasing AAV6 or AAV9 serotypes at the level of the lumbar
spinal cord transduced SMN throughout the spinal cord (Snyder
et al., 2011), and intraspinal delivery of AAV-G-CSF showed a
high transduction efficiency in SMN with modest improvement
in the motor function as well as delayed disease progression and
survival (Henriques et al., 2011).
Gene transduction in the cerebral cortex has also been con-
sidered via intracortical injections using different AAV serotypes.
Different regions of the cerebral cortex have been transduced with
a wide variety of AAV serotypes only to reconfirm the hetero-
geneity and the cellular complexity of the cerebral cortex and
to realize that it is not be possible to transduce distinct neuron
populations with one serotype (Burger et al., 2005; Hutson et al.,
2011). Understanding the identity of neurons that are transduced
in the cerebral cortex has not been easy, but investigating their
axonal projection tracts might suggest their identity. For exam-
ple, detection of transduced axons in the corpus callosum suggests
that transduction of at least a subset of CPN as they cross the
corpus callosum when projecting to the contralateral side of the
cerebral cortex. Similarly, detection of transduced axons within
the CST suggests transduction of subcerebral projection neurons
in the cerebral cortex. Injection of AAV1-eGFP into the motor
cortex resulted in visualization of GFP+ axon fibers within CST,
suggesting that a subset of CSMN were transduced, and the iden-
tity of transduced neurons were further demonstrated with paired
retrograde labeling (Hutson et al., 2011). Taking advantage of
the retrograde transport capabilities and based on the hypotheti-
cal presence of specific receptors for different AAV serotypes, we
have recently reported that AAV2 shows high levels of retrograde
transduction efficiency in CSMN (Jara et al., 2012).
When compared to retrograde labeling techniques, AAV-
mediated gene delivery is far more powerful in clarifying
cytoarchitectural details. In addition, this novel technique has
brought several improvements to previously reported methods
by combining retrograde labeling and transduction applications
to the study of CSMN. Retrograde labeling of CSMN, using dyes
and microspheres, enables visualization of their cell bodies but
fails to reveal the shape and length of dendritic spines. Even
though subtle, these details could be particularly important for
neuron function and connectivity. Since spines are the sites of
active neuronal communication, their modulation, degeneration,
and progressive loss could have implications on disease pathology.
Indeed, there is now building evidence to suggest a link between
spine morphology and a wide variety of neurological diseases
(Penzes et al., 2011). Expressing eGFP gene selectively in CSMN
using AAV-mediated retrograde transduction of the CST allowed
exclusive, homogenous expression of eGFP within CSMN and
analysis of neuronal structures (Figures 2I–K). AAV-mediated
gene delivery demonstrated early and selective apical dendrite
degeneration in the hSOD1G93A ALS mouse model (Figure 1B).
This finding was important because for the first time it deciphered
the cellular events that occur in CSMN. Specifically, apical den-
drited were filled with vacuoles and spines were lost or vastly
degenerated. These defects occurred at P60, a time when SMN
begin to show signs of cellular degeneration, suggesting that
both upper and lower motor neurons degenerate together in syn-
chrony. Neuronal degeneration was previously thought to develop
in a sequence of events that started in the neuromuscular junction
spreading to the SMN and CST until finally reaching the CSMN
cell body. However, the use of AAV-mediated gene delivery pro-
vided a very detailed observation of CSMN and uncovered details
about cellular degeneration within the motor neuron circuitry
that occurs in ALS. Absence of spines and disintegrating apical
dendrites early in the disease may suggest that CSMN do not
receive proper input from other cortical neurons that modulate
their activity and this could be one of the factors contribut-
ing to the observed defects in the motor neuron circuitry. The
importance of early apical dendrite degeneration deserves much
attention as this is the area CSMN activity is heavily modulated
(Shepherd, 2013), and could be one of the underlying causes for
circuitry defects and motor dysfunction (Figure 1B).
Using AAV-mediated gene delivery as a potential therapeu-
tic application to facilitate the repair and survival of CSMN
in neurodegenerative diseases and after spinal cord injury is
a provocative idea. Retrograde transduction also provides the
means to study different subsets of CSMN by injecting into differ-
ent regions of the spinal cord. For instance, cervical and lumbar
injections can be utilized to study neurons that project to differ-
ent spinal cord targets. However, in order to be successful, this
approach would necessitate improvements in transduction speci-
ficity. There are two main approaches to increase specificity: one
is the use of engineered capsid proteins and different serotypes,
and the other is the choice of the promoter used to derive gene
expression. Therefore, a better understanding of the serotype(s)
that transduce CSMN and the use of engineered capsid proteins
or different promoters to drive gene expression would improve
selective transduction.
Even though selective targeting using retrograde labeling in
mice is important, novel approaches need to be developed for
selective CSMN transduction in the motor cortex of patients.
In mice, the CST lies within the dorsal funiculus of the spinal
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cord, but in humans the majority of the CST lies within the
lateral columns, limiting direct access. This anatomical difference
of axon projection path is particularly important. The modula-
tion of genes only in SMN may not be sufficient to implement
a long-term and effective treatment strategy in ALS and other
related motor neuron diseases. Therefore, approaches to trans-
duce CSMN, in addition to SMN, need to be developed.
AAV approaches are not without their limitations. One dis-
advantage is related to the variations introduced by the surgical
techniques. AAV transduction has very low levels of toxicity,
but studies have revealed that intracranial injections might elicit
an immune response (Weinberg et al., 2013). AAV have small
packaging capacity (<5 kb) that might limit genes of interest.
In addition, the timing of intervention and concentration to
achieve a therapeutic effect might be challenging. We antici-
pate that in the future AAV engineering will offer new serotypes
with novel properties that might facilitate the transduction of
CSMN upon direct injection into the motor cortex. Interestingly,
several clinical trials for other neurodegenerative diseases have
explored the possibility of intracranial injections (Hester et al.,
2009) suggesting that in the future similar approaches could be
adapted for transduction of Betz cells in patients. However, prior
to any meaningful cellular repair study, the underlying molecu-
lar causes of cellular vulnerability and degeneration need to be
understood.
GENETIC LABELING OF DISTINCT NEURON POPULATIONS
Genetic labeling allows visualization of cells with spatiotem-
poral resolution in vivo. Compared to surgical approaches,
genetic labeling has several advantages such as reducing vari-
ability from subject to subject, experiment to experiment and
lab-to-lab, ensuring reproducibility of findings. Potential limi-
tations of genetic labeling are the limited availability of unique
genes/markers for specific cell types and the alterations in gene
expression. Certain genes undergo spatiotemporal alterations
throughout development and even environmental factors may
affect control of gene expression by epigenetic mechanisms.
However, advantages of genetic labeling outweigh any disadvan-
tages and are widely used (Huang and Zeng, 2013).
There are three main different ways to achieve genetic tar-
geting: (1) conventional/bacterial artificial chromosome (BAC)
transgene (Schmidt et al., 2013), (2) gene knock-in (Taniguchi
et al., 2011), and (3) gene/enhancer trapping (Leighton et al.,
2001; Kelsch et al., 2012). Conventional or BAC transgene
approaches use a transgene cassette, or BAC, to introduce the pro-
moter/enhancer regions of the gene of interest to drive expression
of a reporter whichmimics endogenous expression patterns. They
are randomly inserted in the genome, which may cause variations
in expression patterns among founder lines. Gene knock-in relies
on inserting the reporter gene in the endogenous location of the
gene of interest to fully recapitulate endogenous expression pat-
terns, however it is technically more challenging and expression
of the target gene itself may be altered even using an internal
ribosome entry site (IRES) sequence. In enhancer trapping, a
reporter driven by a minimal promoter is randomly inserted in
the genome, and local enhancers near the insertion site then
determine expression of the reporter.
Discovery of green fluorescent protein (GFP) (Tsien, 1998) in
1962 was a significant milestone for cell and molecular biology,
and it was granted the Nobel Prize in Chemistry in 2008 (Weiss,
2008). It was not long before GFP was used as a marker for gene
expression in eukaryotes (Chalfie et al., 1994). Since then, there
has been an explosion of its spectral variants with a wide variety
of brightness and colors (Shaner et al., 2005). Transgenic mice
expressing GFP under control of the cytomegalovirus (CMV)
promoter allowed study of the central nervous system at a level
of single individual neuron resolution (van den Pol and Ghosh,
1998). Spectral variants of GFP (yellow, YFP; cyan, CFP; and red,
RFP; collectively called XFP) expressed in transgenic mice under
the control of Thy-1 promoter allowed imaging and identifica-
tion of numerous subsets of neurons (Feng et al., 2000). More
recently, using a cre/lox recombination system to express multi-
ple distinct colors in diverse genetically labeled neurons gave rise
to the “Brainbow” mice (Livet et al., 2007; Cai et al., 2013).
Numerous reporter mouse lines have been generated using
genetic targeting methods and extensively used to study vari-
ous cell types in the mouse CNS, such as layer V pyramidal
neurons (Feng et al., 2000; Yu et al., 2008), cortical interneu-
rons (Chattopadhyaya et al., 2004; Lopez-Bendito et al., 2004;
Taniguchi et al., 2011), basal ganglia (Gerfen et al., 2013), spinal
cord motor neurons and interneurons (Wichterle et al., 2002;
Miles et al., 2004; Chang and Martin, 2011). Of these, Thy-1 XFP
mice are of particular interest as they allow analysis of labeled
cells at a very fine detail, such as dendritic spine dynamics in vivo
(Grutzendler et al., 2002; Oray et al., 2004; Dombeck et al., 2007).
Moreover, they have been used to study mouse models of neu-
rodegenerative diseases at a cellular level, such as dendritic spine
loss in triple transgenic Alzheimer’s disease mice (Bittner et al.,
2010) and motor neuron pathology in the experimental autoim-
mune encephalomyelitis, and mouse model of multiple sclerosis
(Bannerman et al., 2005). Thy1-YFP mice have extensively been
used to study motor systems, not only SMN in mouse models
of ALS (Schaefer et al., 2005; Wong et al., 2009), but also CSMN
(Richter and Roskams, 2009) and their axons in spinal cord injury
(Bareyre et al., 2005) and an ALS mouse model (Ozdinler et al.,
2011).
Another reporter line extensively used to study motor systems
is HB9-GFP, which labels about 90% of SMN in the develop-
ing embryo (Wichterle et al., 2002) but only about half of large
Choline acetyl transferase (ChAT)+ SMN in the ventral horn of
the adult (Chang and Martin, 2011). γ-SMN innervating mus-
cle spindles are GFP− (Shneider et al., 2009). HB9-GFP mice
have been used to follow differentiation ofmouse embryonic stem
cells into motor neurons (Wichterle et al., 2002; Wu et al., 2012).
HP9-GFP+ embryonic stem cell-derived SMN co-cultured with
astrocytes expressing hSOD1G93A displayed increased cell death
and shorter axon length (Dodge et al., 2008). HB9-GFP BACs
have also been used to characterize human embryonic stem cell-
derived motor neuron lineages (Placantonakis et al., 2009) or
facilitate FACS purification of human spinal motor neurons from
embryonic stem cells (Singh Roy et al., 2005). Human embryonic
stem cell-derived motor neurons identified by HB9-GFP expres-
sion showed that SMN with hSOD1 mutations displayed reduced
survival and shorter axons (Karumbayaram et al., 2009). Primary
Frontiers in Neuroanatomy www.frontiersin.org March 2014 | Volume 8 | Article 16 | 8
Jara et al. Novel approaches to study CSMN
and embryonic stem cell-derived motor neurons from HB9-GFP
mice have been used to study neurodegenerative properties of
human SOD1 mutations, showing glia and astrocytes with SOD1
mutations induce neurodegeneration of co-cultured SMN even
when they do not carry the mutation themselves (Di Giorgio
et al., 2007; Nagai et al., 2007). HB9-GFP mice have been used
to study (1) motor axon guidance in vivo by Semaphorin signal-
ing (Huber et al., 2005), (2) in vitro by GDNF chemoattraction
and ephrinA signaling (Dudanova et al., 2010) during normal
development, (3) targeting of regenerating motor axons in vivo
by polysialylated NCAM in the adult (Franz et al., 2005), and (4)
motor axon development in vivo in mouse models of disease such
as SMA (McGovern et al., 2008).
Gene Expression Nervous System Atlas (GENSAT) database
has been invaluable in providing a detailed library of hundreds
of distinct, genetically defined cell populations from engineered
mice utilizing BAC (Gong et al., 2003, 2007; Doyle et al., 2008;
Schmidt et al., 2013). To date, there are almost 400 publica-
tions that use GENSATmice or BACs (www.GENSAT.org). Using
this approach, we generated the UCHL1-eGFP mice in which
the UCHL1 gene promoter was used to drive eGFP expression
(Figure 3) (Yasvoina et al., 2013). CSMN identity of eGFP+ neu-
rons was confirmed by retrograde labeling, molecular marker
expression profile, electrophysiology, cortical circuit mapping,
and mouse genetics studies. CSMN in the motor cortex and their
projections were genetically and stably labeled by GFP expres-
sion from P0 to P800. In the spinal cord, almost all ChAT+
SMN were eGFP+ at birth but by P30 eGFP expression became
restricted to a mixture of small α- and γ-SMN that were resis-
tant to degeneration in motor neuron diseases, such as ALS.
Crossing this reporter mouse with hSOD1G93A ALS mouse model
(Gurney et al., 1994) generated hSOD1G93A-UeGFP mice, which
allowed detailed study of CSMN health. We observed a pro-
gressive degeneration of eGFP+ CSMN, as previously reported
(Ozdinler et al., 2011), with apical dendrite vacuolation and pres-
ence of autophagosomes, suggesting an ongoing intrinsic cellular
degeneration. This novel reporter mouse model for ALS, now
allows the detailed cellular analysis of CSMNwithout the require-
ment of retrograde labeling surgeries, which was not possible
before.
The main challenge of genetic labeling approaches remains
identification of genes/promoters that distinctly and specifi-
cally labels a neuronal subpopulation of interest. Once such
reporters have been identified and characterized, there are
numerous advanced applications. Recent advances in microscopy
allow imaging cells in live animals (intravital imaging) (Pittet
and Weissleder, 2011; Weigert et al., 2013). In vivo imaging
has recently been applied to study spinal cord regeneration
(Laskowski and Bradke, 2013). Optogenetics approaches take
advantage of channelrhodopsin-2, which can be genetically tar-
geted to neurons of interest and used to manipulate neural activ-
ity with millisecond precision using light (Packer et al., 2013).
This allows imaging and long-range circuit mapping of multi-
ple cell types (Atasoy et al., 2008). Optophysiology also grants
success in such studies (Smedemark-Margulies and Trapani,
2013). Recently, optogenetic reactivation of hippocampal neu-
rons activated during fear conditioning was shown to activate fear
memory recall induced by light (Liu et al., 2012). Mosaic analysis
with double markers (MADM) uses a site-specific recombinase to
catalyze inter-chromosomal recombination that creates sparsely
labeled neurons only after recombination (Luo, 2007). Type, den-
sity, and timing of labeling can be controlled by tissue-specific
expression of the recombinase. Genetically encoded fluorescent
protein-based biosensors can be used to study a broad assort-
ment of signaling molecules and networks (Depry et al., 2013).
For example, fluorescent proteins can be used tomonitor protein-
protein interactions in living cells using fluorescent resonance
energy transfer (FRET) microscopy (Stepanenko et al., 2011;
Day and Davidson, 2012). A recent nanobody-based technology
utilizes fluorescent proteins commonly used to label cells and
neurons as scaffolds for cell-specific gene manipulation allowing
selective modulation of diverse GFP-labeled cells across trans-
genic lines such as optogenetic probing of neural circuits (Tang
et al., 2013).
Numerous techniques and applications are being developed
simultaneously to target neurons of interest. Advances in genetic
labeling of select sets of neuron populations coupled with numer-
ous applications that allow their cellular and molecular analysis at
different experimental conditions and disease settings will reveal
the underlying mechanisms for proper cellular function as well
as the molecular networks that are responsible for their selec-
tive vulnerability. This information will be the foundation for
future effective treatments strategies in diseases that primarily
affect distinct neuron populations at initial stages.
CONCLUSION
Techniques allow detailed analysis, but it is our critical thinking
that shapes the field and the future. Many important discov-
eries are made when approaches and critical thinking develop
simultaneously. The definition of “disease,” the description of
pathologies, and our understanding of symptom development
have vastly changed in the last decade. In addition, numerous
new techniques and applications, which allow studies that were
not previously possible, have become available. These two critical
components of innovation have the potential to shape the future
of neurodegenerative diseases once understood and applied prop-
erly. We now have reasons to believe that numerous discoveries
will emerge in the near future.
Recently, the word “spectrum” was introduced when describ-
ing numerous neurodegenerative disorders to highlight the
blurred boundaries among diseases and place them under an
umbrella of systems degeneration with many common features.
This is an important shift from disease-based thinking toward
a more mechanism-oriented understanding that emphasizes the
common underlying pathologies that give rise to different forms
of neurodegeneration. This paradigm shift in our understand-
ing has an impact on defining pathologies, disease mechanisms,
and symptoms. The neurons that show vulnerability and undergo
progressive degeneration have moved center stage. We now real-
ize the importance of understanding the cellular, molecular, and
genetic basis of pathology at a cellular level. This change in critical
thinking proved to be correct by the failures of clinical trials. The
expectation for improved lifespan in mice to translate into suc-
cess in ALS patient survival is now considered mostly unrealistic.
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FIGURE 3 | Genetic Labeling of CSMN. (A) Schematic drawing of genetic
labeling of CSMN by eGFP expression under control of UCHL1 promoter. (B)
A representative sagittal section of a P120 mouse brain showing eGFP+
CSMN and their axons. (C) In motor cortex, eGFP+ CSMN can be seen in
layer 5a and 5b. (C’) Higher magnification of individual representative eGFP+
CSMN in the motor cortex. (D–F) eGFP+ axons of CSMN projecting through
the striatum (D), pons (E), and pyramidal decussation (F). Scale bars: (B) =
1mm, (C,D and E) = 200μm, (C’) = 20μm, (F) = 500μm.
Today, clinical companies are more cautious when making a deci-
sion to move forward, and seek more cell-based evidence that
supports motor neuron survival (Genç and Ozdinler, 2013).
In recent years, there have been significant changes in the
meaning of the word “symptom.” Previously, symptoms were
described as signs of pathology that can be detected by visual
examination or various tests. However, it became obvious that
our ability to detect signs of pathology at a molecular, cellular,
and systems level was different. Even when no obvious signs were
present, the pathology was taking its course at a cellular level.
If the cellular basis of disease causing pathologies was under-
stood, then these findings would set the stage, not only for early
detection of the disease, but also for the development and imple-
mentation of effective long-term treatment strategies. Therefore,
it is important to detect symptoms at a cellular level before
pathologies become evident. We need to develop new approaches
to focus our attention on the neuron, on the cell that is affected
and has become vulnerable. Because if we understand the molec-
ular and genetic basis of neuronal vulnerability at a cellular level,
then we will have the chance to understand the basis of neuronal
pathology and systems degeneration.
Studying CSMN biology is especially challenging, not only
because they are limited in numbers and not easy to identify, but
also because the techniques, technologies, approaches, and model
systems to study them are not easy to develop. Due to species
differences, modeling CSMN degeneration in mice has intrinsic
limitations. Even though a minor defect would lead to a motor
dysfunction in patients, mice would not display an obvious defect.
This could indeed be one of the reasons why the mouse models
of motor neuron diseases do not show a prominent phenotype.
Working in models without an obvious functional readout can be
challenging. However, if the models are built at a cellular level, or
if the focus is shifted from mice to the motor neurons in mice,
then the picture and the scope of perception changes dramati-
cally. At a cellular level, the CSMN in humans and in mice are
almost identical. It is thus important to develop technologies that
reveal the underlying factors that contribute to the cellular vulner-
ability and degeneration. As long as our focus is the neuron and
not the mice, the information gathered from healthy and diseased
neurons would be translational.
Understanding the controls over CSMN health is becoming
very central to numerous neurodegenerative diseases. Here we
reviewed the exciting progress in the study of upper motor neu-
rons. Retrograde labeling is a prominent approach to identify
the location of the neuron and to visualize its cell body. AAV-
mediated retrograde transduction, on the other hand, is not
only a powerful tool to deliver genes of interest, but also impor-
tant to reveal details of cellular cytoarchitecture. However, both
of these applications require surgery and the success of each
experiment mostly depends on surgical expertise and mouse sur-
vival. Genetic labeling that intrinsically targets a distinct neuron
population offers a solution for the potential limitations of retro-
grade labeling surgeries. Generation and characterization of the
UCHL1-eGFPmouse, in which the CSMN are genetically labeled,
has been pivotal for overcoming numerous important limitations
by allowing in vivo visualization and cellular analysis of neurons
that are vulnerable in neurodegenerative diseases.
With the advancements made in the study of CSMN biol-
ogy, the future awaits numerous important discoveries. FACS
purification coupled with in vitro culturing will allow novel drug
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screening and verification platforms using motor neuron health
as a readout for success. This application has the potential to dis-
cover new molecules and compounds for future clinical trials. In
addition, development of AAV-mediated gene delivery, together
with the identification of new genes and pathways that are impor-
tant for disease pathology will enable direct cellular therapies into
the motor cortex of patients improving the survival of upper
motor neurons and enhancing their connectivity. Identification
of the cellular and molecular basis of CSMN vulnerability will be
revealed, paving the way for understanding the cellular pathways,
networks, and dynamics that are important to improve motor
neuron health.
We live in very exciting times due to the numerous improve-
ments in our critical thinking of neurodegenerative diseases, and
the technologies that support discoveries are developing faster
than ever. The new knowledge gathered from neurons of interest
will enable development of novel effective long-term treatment
strategies and has the potential to expedite new discoveries that
will enable improved health in patients.
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